Enlivex prices $7.5 million registered direct offering
ENLV•
ENLV•Enlivex entered an agreement for a $7.5 million registered direct offering of ordinary shares or pre-funded warrants, with accompanying warrants. The offering includes an initial $500,000 closing and ten $700,000 monthly closings; warrants could generate another $9 million if fully cash-exercised.
Enlivex priced the securities at $1.315 per ordinary share or $1.314 per pre-funded warrant, with accompanying ordinary warrants. The $500,000 initial closing is expected November 17, 2026, followed by ten $700,000 monthly closings from December 1, 2026, through September 1, 2027. The warrants are immediately exercisable at $1.578 per share, expire three years after the initial closing and could generate $9 million if fully cash-exercised. Net proceeds are intended for clinical and development activities, potential acquisitions and in-licensing, and general corporate purposes.